labiotech.eu /3 weeks ago

TROP2 ADCs: The race to capture the next oncology opportunity 

Look into the landscape around TROP2 ADCs as frontrunners aim to expand and the next wave aims to develop safer drugs. The post TROP2 ADCs: The race to capture the next oncology op...

Read source
qchron.com /1 month ago

ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Nega...

SHANGHAI, Oct. 18, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present Phase II...

Read source
biopharmadive.com /2 weeks ago

At ASH, drugmakers to showcase early data for three-pronged cancer therapies

J&J and AbbVie are among the companies advancing “trispecific” antibodies that could become another step forward in treatment for multiple myeloma.

Read source
biopharmadive.com /1 month ago

Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial

The better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, according to one analyst.

Read source
biopharmadive.com /3 weeks ago

BioNTech, DualityBio say ADC had ‘modest’ benefit in breast cancer study

The companies said the findings suggest the treatment has a “limited” impact in HER2-low breast cancer, an area where AstraZeneca and Daiichi Sankyo’s Enhertu has already set a hig...

Read source
bioengineer.org /1 month ago

Skin Side Effects of Breast Cancer Drug Sacituzumab Govitecan Are Mostly Mild, Global Study Finds

Sacituzumab govitecan has become one of the most consequential weapons in modern oncology, a so-called antibody–drug conjugate that delivers a potent chemotherapy payload directly...

Read source
newswire.com /1 month ago

Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development

Company Making Critical Progress in Scalable Manufacturing and Preparing the Lead Trispecific Candidate for Future Human TestingTrispecifics Combine Three Complementary Cancer-Figh...

Read source
qchron.com /4 weeks ago

Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-ta...

Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity observed acr...

Read source
genengnews.com /1 month ago

Roche, Hansoh Launch Up-to-$15B+ Cancer ADC Collaboration

The companies' strategic collaboration will consist of two preclinical Hansoh ADC programs and “multiple” ADC programs based on Roche-identified targets, to be developed through Ha...

Read source
labiotech.eu /1 month ago

B7-H3 ADCs: A new contender in small cell lung cancer and beyond 

Delve into the field of B7-H3 ADCs, a new contender in SCLC cancer as Hansoh Pharma and Medilink bring momentum with positive results. The post B7-H3 ADCs: A new contender in small...

Read source
labiotech.eu /2 days ago

The ADC patent cliff: a turning point for rare cancer treatment

Our guest today is Robert Andrews, Partner and Patent Attorney at Mewburn Ellis. Robert has spent more than 20 years advising ADC companies on patent strategy. The post The ADC pat...

Read source
seekingalpha.com /4 weeks ago

Eli Lilly releases promising early-stage data on ADC for ovarian cancer

Read source
bioengineer.org /1 week ago

Second-Line Trastuzumab Deruxtecan Yields 23-Month Progression-Free Survival in Gastroesophageal Cancer

A 63-year-old patient with HER2-positive metastatic gastroesophageal junction adenocarcinoma achieved 23 months of progression-free survival on second-line trastuzumab deruxtecan f...

Read source
biopharmadive.com /3 weeks ago

Novel protein and peptide therapeutics

Explore manufacturing challenges and solutions for ADCs, bispecifics, peptides and more.

Read source
qchron.com /1 month ago

Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential...

Includes worldwide license to ABO2203, Abogen's mRNA-encoded CD19xCD3 T-Cell Engager

Read source
qchron.com /1 week ago

Antengene Presents Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026

SHANGHAI and HONG KONG, Nov. 11, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company ded...

Read source
pharmexec.com /1 month ago

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Tukysa Plus Trastuzumab and Pertuzumab]]>

Read source
medcitynews.com /1 month ago

AstraZeneca Places a $2B Bet on a Summit Therapeutics Cancer Drug

AstraZeneca’s equity investment in Summit Therapeutics comes with plans for clinical trial collaborations. The deal brings AstraZeneca into a growing group of pharmaceutical compan...

Read source
pharmexec.com /3 days ago

<![CDATA[DISCO, AbbVie Sign AND-Gated Bispecific Deal Worth Up to $2.5B]]>

Read source
biopharmadive.com /5 days ago

CG Oncology drug delivers ‘exceptional’ results in key bladder cancer trial

CG’s therapy cretostimogene cut the risk of recurrence by 68% when administered after surgery, far surpassing Wall Street’s expectations and lifting company shares. 

Read source
pharmexec.com /1 month ago

<![CDATA[FDA Approves Tukysa Plus Trastuzumab and Pertuzumab as First-Line Maintenance Treatment for HER2-Positive Me...

Read source
pharmexec.com /1 month ago

<![CDATA[Regeneron and Sanofi Expand Antibody Alliance with Four New Drugs]]>

Read source
genengnews.com /1 month ago

Ginkgo Datapoints, Apheris Announce Founding Members of Antibody Developability Consortium

The consortium aims to address antibody development bottlenecks by creating standardized datasets and AI models that support earlier risk detection and more informed candidate sele...

Read source
newswire.com /6 days ago

Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Re...

Mipletamig achieves 79% remission rate in high-risk TP53-mutated AML, nearly double the published historical benchmarkTen of 47 patients receiving mipletamig combination therapy ad...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.